systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-96Research ArticleКАРДИОЛОГИЯCARDIOLOGYЛерканидипин – новый блокатор кальциевых каналов: эффективность применения у больных артериальной гипертониейЧихладзеН. М.noemail@neicon.ruЧазоваИ. Е.noemail@neicon.ruРоссийский кардиологический научно-производственный комплекс Росздрава, МоскваRussian Federation200723122022514548Copyright © Чихладзе Н.М., Чазова И.Е., 20222022Чихладзе Н.М., Чазова И.Е.Чихладзе Н.М., Чазова И.Е.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/96

Блокаторы кальциевых каналов (БКК) уже более четверти века широко применяются в клинической практике для лечения артериальной гипертонии (АГ) и входят в число основных классов антигипертензивных препаратов. Появление новых представителей БКК привлекает к себе особый интерес с позиции анализа особенностей их фармакодинамики, фармакокинетики, терапевтической эффективности и переносимости в сопоставлении с другими антигипертензивными препаратами. Представитель последнего поколения БКК лерканидипин по химической структуре относится к дигидропиридиновым БКК, которые отличаются от недигидропиридинов (верапамил, дилтиазем) более высокой селективностью к медленным кальциевым каналам гладкомышечных клеток сосудов по сравнению с кальциевыми каналами миокарда. В исследовании in vitro продемонстрирована бЧльшая вазоселективность лерканидипина по сравнению с другими БКК: выше, чем у амлодипина, фелодипина, нитрендипина и лацидипина [1]. В соответствии с вазоселективностью лерканидипин проявляет менее выраженную отрицательную инотропную активность по сравнению с другими антагонистами кальция как в условиях in vitro, так и in vivo. В экспериментальных условиях отрицательная инотропная активность лерканидипина оказалась менее выраженной, чем у фелодипина, нитрендипина, лацидипина и амлодипина

ReferencesAngelico P, Guarneri L, Leonardi A et al. Vascular - selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J Pharm Pharmacol 1999; 51: 709–14.Angelico P, Guarneri L, Leonardi A et al. Vascular - selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J Pharm Pharmacol 1999; 51: 709–14.Soma M.R, Natali M, Donetti E et al. Effect of lercanidipine its (R) - enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits. Br J Pharmacol 1998; 125: 1471–6.Soma M.R, Natali M, Donetti E et al. Effect of lercanidipine its (R) - enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits. Br J Pharmacol 1998; 125: 1471–6.Rachmani R, Levi Z, Zadok B.S et al. Losartan and lercanidipine attenuate low - density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study. Clin Pharmacol Ther 2002; 72 (3): 302–7.Rachmani R, Levi Z, Zadok B.S et al. Losartan and lercanidipine attenuate low - density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study. Clin Pharmacol Ther 2002; 72 (3): 302–7.Lozano J.V, Sanchis C, Llisterri J.L. Efficacy of lercanidipine in poorly controlled hypertensive patients who follow a home blood pressure measurement training program [abstract no. R190]. J Hypertens 2002; 20 (Suppl. 4): S376.Lozano J.V, Sanchis C, Llisterri J.L. Efficacy of lercanidipine in poorly controlled hypertensive patients who follow a home blood pressure measurement training program [abstract no. R190]. J Hypertens 2002; 20 (Suppl. 4): S376.Barchielli M, Dolfini E, Farina P et al. Clinical pharmacokinetics of lercanidipine. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S1–15Barchielli M, Dolfini E, Farina P et al. Clinical pharmacokinetics of lercanidipine. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S1–15Barrios V, Navarro A, Esteras A et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Press 2002; 11 (2): 95–100.Barrios V, Navarro A, Esteras A et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Press 2002; 11 (2): 95–100.Policicchio D, Magliocca R, Malliani A. Efficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: a comparative study with slow - release nifedipine. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S31–5.Policicchio D, Magliocca R, Malliani A. Efficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: a comparative study with slow - release nifedipine. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S31–5.Romito R, Pansini M.I, Perticone F et al. Comparative effect of of lercanidipine lercandipine, felodipine and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercandipine in Adults (LEAD) study. J Clin Hypertens 2003; 5 (4): 249–53.Romito R, Pansini M.I, Perticone F et al. Comparative effect of of lercanidipine lercandipine, felodipine and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercandipine in Adults (LEAD) study. J Clin Hypertens 2003; 5 (4): 249–53.Pedrinelli R, Dell’Omo G, Nuti M et al. Heterogenous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients. J Hypertens 2003; 21: 1969–73.Pedrinelli R, Dell’Omo G, Nuti M et al. Heterogenous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients. J Hypertens 2003; 21: 1969–73.Cavallini A, Terzi G. Effects of antihypertensive therapy with lercanidipine and verapamil on cardiac electrical activity in patients with hypertension: a randomized, double - blind pilot study. Curr Ther Res 2000; 61 (7): 477–87.Cavallini A, Terzi G. Effects of antihypertensive therapy with lercanidipine and verapamil on cardiac electrical activity in patients with hypertension: a randomized, double - blind pilot study. Curr Ther Res 2000; 61 (7): 477–87.Macchiarulo C, Pieri R, Mitolo D.C et al. Antihypertensive effects of six calcium antagonists: evidence from Fourier analysis of 24-hour ambulatory blood pressure recordings. Curr Ther Res 2001; 62 (4): 236–53.Macchiarulo C, Pieri R, Mitolo D.C et al. Antihypertensive effects of six calcium antagonists: evidence from Fourier analysis of 24-hour ambulatory blood pressure recordings. Curr Ther Res 2001; 62 (4): 236–53.Fogari R, Malamani G.D, Zoppi A et al. Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double - blind, randomized, parallel group study. Curr Ther Res Clin Exp 2000; 61: 850–62.Fogari R, Malamani G.D, Zoppi A et al. Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double - blind, randomized, parallel group study. Curr Ther Res Clin Exp 2000; 61: 850–62.Morisco C, Trimarco B. Efficacy and tolerability of lercanidipine in comparison to and in combination with atenolol in patients with mild to moderate hypertension in a double blind controlled study. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S26–30.Morisco C, Trimarco B. Efficacy and tolerability of lercanidipine in comparison to and in combination with atenolol in patients with mild to moderate hypertension in a double blind controlled study. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S26–30.James I.G.V, Jones A, Davies P. A randomised, double - blind, double - dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J Hum Hypertens 2002; 16 (8): 605–10.James I.G.V, Jones A, Davies P. A randomised, double - blind, double - dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J Hum Hypertens 2002; 16 (8): 605–10.Barbagallo Sangiorgi G, Putignano E, Calcara L et al. Efficacy and tolerability of lercanidipine vs. captopril in patients with mild to moderate hypertension in a double - blind controlled study. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S36–9.Barbagallo Sangiorgi G, Putignano E, Calcara L et al. Efficacy and tolerability of lercanidipine vs. captopril in patients with mild to moderate hypertension in a double - blind controlled study. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S36–9.Notarbartolo A, Rengo F, Scafidi V et al. Long - term effects of Evaluation of lercanidipine on the lipoprotein and apolipoprotein profile of patients with mild - to - moderate essential hypertension. Curr Ther Res 1999; 60 (4): 228–36.Notarbartolo A, Rengo F, Scafidi V et al. Long - term effects of Evaluation of lercanidipine on the lipoprotein and apolipoprotein profile of patients with mild - to - moderate essential hypertension. Curr Ther Res 1999; 60 (4): 228–36.Paterna S, Licata A, Arnone S et al. Lercanidipine in two different dosage regimens as a sole treatment for severe essential hypertension. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S50–3.Paterna S, Licata A, Arnone S et al. Lercanidipine in two different dosage regimens as a sole treatment for severe essential hypertension. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S50–3.Rengo F, Romis L. Activity of lercanidipine in double - blind comparison with nitrendipine in combination treatment of resistant essential hypertension. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S54–8.Rengo F, Romis L. Activity of lercanidipine in double - blind comparison with nitrendipine in combination treatment of resistant essential hypertension. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S54–8.Barbagallo M, Barbagallo Sangiorgi G. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin Exp Res 2000; 12 (5): 375–9.Barbagallo M, Barbagallo Sangiorgi G. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin Exp Res 2000; 12 (5): 375–9.Leonetti G, Magnani B, Pessina A.C et al. Tolerability of longterm treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002; 15 (11): 932–40.Leonetti G, Magnani B, Pessina A.C et al. Tolerability of longterm treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002; 15 (11): 932–40.Viviani G.L. Lercanidipine in type II diabetic patients with mild moderate arterial hypertension. J Cardiovasc Pharmacol 2002; 40 (1): 133–9.Viviani G.L. Lercanidipine in type II diabetic patients with mild moderate arterial hypertension. J Cardiovasc Pharmacol 2002; 40 (1): 133–9.Herrera J, Ghais Z, Gonzalez L. Antihypertensive treatment with a calcium channel blocker in postmenopausal women: prospective study in a primary health care setting [abstract no. P0680]. J Hypertens 2002; 20 (Suppl. 4): S162.Herrera J, Ghais Z, Gonzalez L. Antihypertensive treatment with a calcium channel blocker in postmenopausal women: prospective study in a primary health care setting [abstract no. P0680]. J Hypertens 2002; 20 (Suppl. 4): S162.Fogari R, Mugellini A, Corradi L et al. Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients [abstract no. P1.191]. J Hypertens 2000; 18 (Suppl. 2): S65.Fogari R, Mugellini A, Corradi L et al. Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients [abstract no. P1.191]. J Hypertens 2000; 18 (Suppl. 2): S65.S’anchez A, Sayans R, Alvarez J.L et al. Left ventricular hypertrophy regression after a short antihypertensive treatment with lercanidipine vs. enalapril [abstract no. 12]. Fourth European Meeting on Calcium Antagonists; 1999 Oct 27–29; Amsterdam.S’anchez A, Sayans R, Alvarez J.L et al. Left ventricular hypertrophy regression after a short antihypertensive treatment with lercanidipine vs. enalapril [abstract no. 12]. Fourth European Meeting on Calcium Antagonists; 1999 Oct 27–29; Amsterdam.Schwinger R.H.G, Schmidt-Mertens A. The new lipophillic calcium channel blocker lercanidipine combines high antihypertensive efficacy with low side effects [abstract no. P1-7]. Dtsch Med Wochenschr 2002; 127 (Suppl. 1): S13.Schwinger R.H.G, Schmidt-Mertens A. The new lipophillic calcium channel blocker lercanidipine combines high antihypertensive efficacy with low side effects [abstract no. P1-7]. Dtsch Med Wochenschr 2002; 127 (Suppl. 1): S13.Borghi C, Prandin M.G, Dormi A et al. Improved tolerability of the dihydropyridine calcium - channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press 2003; 12 (Suppl. 1): 1–8.Borghi C, Prandin M.G, Dormi A et al. Improved tolerability of the dihydropyridine calcium - channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press 2003; 12 (Suppl. 1): 1–8.

The authors declare that there are no conflicts of interest present.